These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 35462369)
1. Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D). Gang S; Khetan P; Varade D; Chinta VR; Mavani S; Gupta U; Reddy SVK; Rajanna S; Jeloka T; Ruhela V; Kansagra K; Kanani P; Bhatt J; Zala K; Am J Nephrol; 2022; 53(5):343-351. PubMed ID: 35462369 [TBL] [Abstract][Full Text] [Related]
2. Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND). Agrawal D; Varade D; Shah H; Nazar A; Krishnan J; Shukla V; Ramakrishna C; Bandara Galahitiyawa MC; Mavani SB; Rajanna S; Jikki P; De Silva S; Ruhela V; Koradia P; Kansagra K; Kanani P; Sharma N; Zala K; Parmar D; Am J Nephrol; 2022; 53(5):352-360. PubMed ID: 35462372 [TBL] [Abstract][Full Text] [Related]
3. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Coyne DW; Singh AK; Lopes RD; Bailey CK; DiMino TL; Huang C; Connaire J; Rastogi A; Kim SG; Orias M; Shah S; Patel V; Cobitz AR; Wanner C Clin J Am Soc Nephrol; 2022 Sep; 17(9):1325-1336. PubMed ID: 35918106 [TBL] [Abstract][Full Text] [Related]
4. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study. Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890 [TBL] [Abstract][Full Text] [Related]
5. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724 [TBL] [Abstract][Full Text] [Related]
6. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD. Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481 [TBL] [Abstract][Full Text] [Related]
9. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393 [TBL] [Abstract][Full Text] [Related]
11. Effects of Molidustat in the Treatment of Anemia in CKD. Macdougall IC; Akizawa T; Berns JS; Bernhardt T; Krueger T Clin J Am Soc Nephrol; 2019 Jan; 14(1):28-39. PubMed ID: 30559105 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis. Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478 [TBL] [Abstract][Full Text] [Related]
13. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Patel M; Thimons DG; Winston JL; Langholff W; McGowan T J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804 [TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy and Safety Study of Darbepoetin Alfa El-Ashmawy NE; Khedr EG; Kotb NS; Salem F; Ibrahim AO Curr Drug Saf; 2022; 17(3):250-258. PubMed ID: 34814819 [TBL] [Abstract][Full Text] [Related]
16. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Singh AK; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Perkovic V; Solomon S; Wanner C; Waikar SS; Wheeler DC; Wiecek A Nephrol Dial Transplant; 2022 Apr; 37(5):960-972. PubMed ID: 33744933 [TBL] [Abstract][Full Text] [Related]
17. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. Azmandian J; Abbasi MR; Pourfarziani V; Nasiri AA; Ossareh S; Ezzatzadegan Jahromi S; Sanadgol H; Amini S; Shahvaroughi Farahani A Am J Nephrol; 2018; 48(4):251-259. PubMed ID: 30253403 [TBL] [Abstract][Full Text] [Related]
18. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U; Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476 [TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A; Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]